Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Summit Therapeutics (SMMT) Enterprise Value: 2016-2025

Historic Enterprise Value for Summit Therapeutics (SMMT) over the last 10 years, with Sep 2025 value amounting to $15.1 billion.

  • Summit Therapeutics' Enterprise Value fell 4.22% to $15.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $14.0 billion, marking a year-over-year decrease of 9.42%. This contributed to the annual value of $12.7 billion for FY2024, which is 675.88% up from last year.
  • As of Q3 2025, Summit Therapeutics' Enterprise Value stood at $15.1 billion, which was down 2.56% from $15.5 billion recorded in Q2 2025.
  • In the past 5 years, Summit Therapeutics' Enterprise Value ranged from a high of $15.8 billion in Q3 2024 and a low of -$5.2 million during Q3 2022.
  • Moreover, its 3-year median value for Enterprise Value was $5.4 billion (2024), whereas its average is $7.9 billion.
  • In the last 5 years, Summit Therapeutics' Enterprise Value tumbled by 101.07% in 2022 and then surged by 21,341.93% in 2023.
  • Quarterly analysis of 5 years shows Summit Therapeutics' Enterprise Value stood at $191.1 million in 2021, then grew by 8.35% to $207.0 million in 2022, then surged by 693.67% to $1.6 billion in 2023, then soared by 675.88% to $12.7 billion in 2024, then declined by 4.22% to $15.1 billion in 2025.
  • Its last three reported values are $15.1 billion in Q3 2025, $15.5 billion for Q2 2025, and $13.9 billion during Q1 2025.